key: cord-0875029-phailyjd
authors: Albalawi, Omar M.; Alomran, Maha I.; Alsagri, Ghada M.; Althunian, Turki A.; Alshammari, Thamir M.
title: Analyzing the U.S. Post-marketing safety surveillance of COVID-19 vaccines
date: 2021-12-31
journal: Saudi Pharm J
DOI: 10.1016/j.jsps.2021.12.008
sha: 79d89a18343ac59d6a6c9cb3563aa2ccae2788cd
doc_id: 875029
cord_uid: phailyjd

INTRODUCTION: Since December 2020, three COVID-19 vaccines have been authorized in the United States (U.S.) and were proceeded by large immunization programs. The aim of this study was to characterize the U.S. post-marketing safety (PMS) profiles of these vaccines with an in-depth analysis of mortality data. METHODS: This was a retrospective database analysis study. Details of the U.S. PMS reports (15 December 2020 to 19 March 2021) of the three vaccines (Pfizer-BioNTech, Moderna, and Janssen Ad26.COV2.S) were retrieved from the U.S. Vaccine Adverse Event Reporting System (VAERS). A descriptive analysis was conducted to characterize the reported adverse events (AEs). A comparative (Pfizer-BioNTech vs. Moderna) analysis of mortality was conducted. The mean count ratio of death between the two vaccines was estimated using a negative binomial regression model adjusting for the measured confounders. RESULTS: A total of 44,451 AE reports were retrieved (corresponding to 0.05% of the U.S. population who received at least one dose). The most commonly reported AEs were injection site reactions (30.4% of the reports), pain (reported in 26.7% of the reports), and headache (18.6% of the reports). Serious AEs were reported in only 14.6% of the reports with 4,108 hospitalizations. The total number of deaths was 1,919 with a mean count ratio of Moderna (n = 997) vs. Pfizer-BioNTech (n = 899) of 1.07 (95% confidence interval 0.86 to 1.33). CONCLUSIONS: The vast majority of PMS AEs in the U.S. were non-serious, and the number of serious AEs is very low given the total number of vaccinated U.S. population.

The outbreak of severe acute respiratory syndrome coronavirus disease 2 (known as was first reported on 31 December 2019in China (Wu et al., 2020) . As of 19 March 2021, more than 29.71 million cases were identified in the United States (U.S.) with a total number of death cases of at least 540,733 (Centers for Disease Control and Prevention (CDC), 2021a). The first COVID-19 vaccine (Pfizer-BioNTech) was authorized for the use in the U.S. on 11 December 2020 (U.S. Food and Drug Administration, 2020a), which was followed by the approval of two other vaccines: Moderna ( U.S. Food and Drug Administration, 2020b) , and Janssen Ad26.COV2.S (U.S.Food and Drug Administration, 2021a) . All these three vaccines were authorized under the Emergency Use Authorization (EUA) framework (i.e. accompanied with a degree of pre-marketing safety uncertainty) ( U.S. Food and Drug Administration,2021b) ; thus necessitating an extensive post-marketing safety (PMS) assessment in the context of pharmacovigilance activities.

In Phase III clinical trials, the most commonly identified non-serious AEs related to these vaccines were pain at the injection site, fatigue, headache, myalgia, chills, arthralgia, and fever (Baden et al., 2020; Polack et al., 2020; Sadoff et al., 2021) . These findings were also commonly reported after the U.S. Food and Drug Administration authorization of Pfizer-BioNTech and Moderna vaccines (in addition to dizziness and nausea) (Julianne et al., 2021) . In Phase III clinical trials, the incidence of serious AEs was low, with no differences between the vaccines and placebo groups (0.4 to 0.6%) (Baden et al., 2020; Polack et al., 2020; Sadoff et al., 2021) . The number of death cases was lower in the three vaccine groups compared with placebo groups (2 to 6 vs. 4 to 16; respectively) (Baden et al., 2020; Polack et al., 2020; Sadoff et al., 2021) . In the first US PMS report, serious AEs were reported in 640 reports(113 deathcases) after COVID-19 vaccinations (Julianne et al., 2021) . Given the degree of uncertainty associated with the safety profile of these vaccines due to their approved under EUA, we aimed at evaluating the PMS of the current COVID-19 vaccines authorized for use in the U.S. in the context of spontaneous reporting with an in-depth analysis of mortality data.

This retrospective analysis was conducted using the publically available database of the U.S. Vaccine Adverse Event Reporting System (VAERS). VAERS is a critical component of the national passive surveillance (spontaneous reporting) system of the approved vaccines in the U.S. (CDC, 2021a) . VAERS was established in 1990 under the joint administration of CDC and the U.S. FDA (Tom et al., 2015) . The purposes of VAERS have been to detect early warning safety signals and to generate hypotheses about possible new unexpected AEs or changes in the frequency of the known ones (CDC, 2021b; Tom et al., 2015) . Reports in VAERS are sent from manufacturers, healthcare professionals and the public (CDC, 2021b). It has been a source of data for many published studies (DiMiceli et al., 2006; Shimabukuro et al., 2021; Tom et al., 2015; Welsh et al., 2021) .

Data were extracted from 15 December 2020 to 19 March 2021. Data (available in tables) were assessed and cleaned by of the research team. Demographics (e.g., person, place, and time), onset intervals, and potential confounders in the mortality assessments (cardiovascular diseases [CVD] , respiratory diseases, diabetes, renal diseases, and to the history of allergies or allergic were identified. AEs were classified as serious AEs defined by the federal regulatory (U.S. Food and Drug Administration, 2021c).

Distributions of non-serious and serious AEs per state, gender, vaccine, age group, and time of AE were summarized. These findings were provided using a population-level estimate (i.e. based on the number of people who received at least one dose of the study vaccine in the U.S up to 19 March 2021 as a denominator), and using the reporting rate An in-depth, comparative analysis of mortality between Pfizer-BioNTech vs. Moderna was conducted with the mean count ratio as a primary effect estimate (Janssen Ad26.COV2.S was excluded from the analysis given its recent approval). The mean count ratio of death between the two vaccines was estimated using a negative binomial regression model adjusting for the measured confounders (age, gender, history of allergy, onset intervals after the first dose, and the presence of several chronic diseases [Cardiovascular disease, diabetes, a respiratory disease, and renal disease]). The negative binomial model was used instead of a poisson model due to the presence of overdispersion. All analyses were completed using RStudio Version 1.4.1103.

By 19 March 2021, 44,451 AE reports (0.05% of the total 85,778,745 vaccinated U.S. population) were extracted from VAERS. The median age in the identified reports was 49 years (range 13-115 years), and most symptoms occurred within two days of the vaccination (range 0-64 days). More than two-third of patients were female, and less than one-third have a type of allergy (Table 1) 

Our study showed that most of the reported AEs among those who received the three approved COVID-19 vaccines in the US were non-serious. The study also showed no emerging trends in unknown serious AEs (the most commonly reported serious AEs were reported were hospitalization, followed by death and life threating). Finally, our study showed that both vaccines (Moderna vs. Pfizer-BioNTechCOVID) have a similar probability of death.

The proportion/report rate of AEs observed in our study are consistent with the findings of the previous studies (from a population-level and rate perspectives) that used a The number of the retrieved AE reports allowed us to extend the PMS assessment to diverse US populations and to populations that were not covered in the pre-marketing clinical development programs of the three approved vaccines. However, our analyses were conducted in the context of the spontaneous (unsolicited) AE reporting passive framework of VAERS. This precluded us from running all typical risk-, rate-or hazardbased analyses (i.e. having the actual population of the study as a denominator). It also precluded us from running several comparative analyses among the three vaccines adjusting for the relevant measured confounders. Our study has several limitations. First limitation to this study is that the data source we used (i.e., VAERS) cannot and does not determine whether a vaccine caused these AEs. Furthermore, our data was from December 2020 to March 2021, which was at the beginning of the rolling out COVID-19 vaccines, and more data are added to VAERS, which might not have the same patterns that our data did. Future real-world studies using electronic health records (EHRs) would be more informative in the post-marketing safety assessment of these vaccines.

Our study showed that the vast majority of the PMS AEs in the U.S. were non-serious and comparable to the findings of the Phase III trials. The study also showed no emerging trends in unknown serious AEs. Finally, we did not find any differences in the number of reported death cases between Moderna vs. Pfizer-BioNTechCOVID-19

vaccines. Future large-scale, real-world studies are needed to confirm the findings of this study.

The views expressed in this paper are those of the author(s) and not do not necessarily reflect those of the SFDA or its stakeholders. Guaranteeing the accuracy and the validity of the data is a sole responsibility of the research team". 

Moderna COVID-19 Vaccine

What is a Serious Adverse Event?

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

About The Vaccine Adverse Event Reporting System (VAERS

Vaccination of yeast sensitive individuals: Review of safety data in the US vaccine adverse event reporting system (VAERS)

Serious adverse events reported from the COVID-19 vaccines: A descriptive study based on WHO database

Emergency Use Authorization for Vaccines to Prevent COVID-19

Ruiling Liu1; Tanya Myers1; Narayan Nair2; Stacey Martin1; Thomas Clark1; Lauri Markowitz1; Nicole Lindsey1; Bicheng Zhang1; Charles Licata1; Amelia Jazwa1; Mark Sotir1

Pfizer-BioNTech COVID-19 Vaccine EUA Letter of Authorization

Female-Male Differences in COVID Vaccine Adverse Events Have Precedence in Seasonal Flu Shots: A Potential Link to Sex-Associated Baseline Gene Expression Patterns

Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS)

The outbreak of COVID-19: An overview